PRESS RELEASE - More than two out of three U.S. adults believe that the personal use of cannabis should be legal, according to nationwide polling data compiled and released by the Pew Research Center.

“The percentage of the public who favors adult-use marijuana legalization has skyrocketed over the past three decades and shows no signs of abating,” NORML Executive Director Erik Altieri said. “As more and more states have moved forward with their own marijuana liberalization policies in recent years, public support has only grown stronger. At a time when the political divide is larger than ever, the issue of marijuana legalization is one of the few policy issues upon which most Americans agree.”

Sixty-seven percent of respondents say that the “use of marijuana should be made legal.” That is the highest percentage of support ever recorded by Pew, which has been surveying Americans’ attitudes on marijuana policy since 1969. Public support for legalization has more than doubled in the past decade.

The Pew survey is the fourth national poll released in recent weeks showing majority support for cannabis legalization. Recently compiled polling data by Gallup and the Public Religion Research Institute both reported that two-thirds of Americans endorse legalization, while survey data compiled by Harvard reported that 62 percent of U.S. adults back the policy change.

Consistent with other national surveys, support for adult-use legalization was strongest among self-identified Democrats (78 percent) and Millennials (76 percent), but was weaker among Republicans (55 percent) and those born before 1945 (35 percent).

According to Pew, in 1989 only 16 percent of U.S. adults believed that cannabis should be legalized.

All Alchemy, Chroma, Delta 8, Co2lors and CBx Sciences Amplify and Meditate vape products are manufactured in compliance with the CannApprove protocols, which apply to ingredients, components, hardware, manufacturing processes and packaging.

“Quality and safety are at the center of what we do and have done for nearly a decade,” said Harvest CEO Steve White. “CannApprove represents the rigorous steps and standards we employ to provide quality products for consumers and our patients. We go above and beyond the testing requirements in many jurisdictions where we operate and at a time when vaping products are under immense scrutiny, Harvest’s efforts demonstrate our leadership role over quality control.”

“Harvest’s consumer safety team includes medical professionals, scientists, researchers and former regulators that have been implemented these protocols for many years and are excited to give consumers a clear picture of the steps we’ve always taken for their benefit,” said Harvest Chief Scientist Noel Palmer, PhD. “We have played a role in writing some of the most stringent cannabis regulations in the nation and we bring that diligence to the work we do to protect our patients.”

The CannApprove testing and safety protocols include:

• Stringent Third Party (or Internal) Testing: Harvest's ingredients are tested internally or by third party laboratories to be free from potentially toxic ingredients like vitamin E, caprylic acid, mineral oil, squalene, polyethylene glycol (PEG), propylene glycol (PG), vegetable glycerin (VG), medium chain triglycerides (MCT) oils and triethyl citrate.
• Quality Ingredients: The company's THC vape pens and cartridges only use pharmaceutical grade cannabis from sources that have been tested for potency and to be free from residual solvents, heavy metals, pesticides, herbicides, mycotoxins, microbiological and other contaminants. The flavors Harvest use are all natural, nothing synthetic.
• Seed to Sale Testing: Harvest tests throughout the entire process, from seed to sale, and THC vaping products have completed the CannApprove program that can only be earned by following a rigorous testing process.
• Going Above and Beyond State Regulations: The company goes above and beyond most state requirements and apply rigorous testing standards to our products for the patients we serve. It ensures compliance with all state-specific regulations regarding use of ingredients.
• Thoroughly Analyzed Components: The cartridges, coils, wicking and soldering materials used in Harvest's products go through our state-of-the-art laboratories in Colorado, California or Florida for thorough testing at the elemental level for heavy metals and other contaminants before they are released to our facilities across the country.
• Responsible Manufacturing Practices: The company's hardware is produced and packaged in Good Manufacturing Practice (GMP) audited facilities or are overseen by GMP-experienced personnel and must include Certificates of Analysis, the gold standard in pharmaceutical manufacturing.
• Diligent Post-Fill Testing: Harvest's filled products are tested for potency and to be free from heavy metals, residual solvents, pesticides, herbicides, mycotoxins, and microbiological and other contaminants.
• Device and Packaging Safety: The company exclusively uses child-proof and tamper-evident packaging. Harvest runs routine hardware audits to ensure our products do not allow for manipulation above manufacturer temperature guidelines. These steps ensure that its hardware as sold reproducibly reaches consistent temperatures safely and helps prevent contamination and modification for illicit use.
• Dedicated Professional Team: Harvest has a robust team of professionals with backgrounds as regulators, medical professionals, scientists and researchers led by Chief Scientist Noel Palmer, PhD. Dr. Palmer and his team played a role in writing some of the most stringent cannabis regulations in the nation.

Ashkelon, November 13, 2019 - PRESS RELEASE - Together, which specializes in cultivating and producing medical cannabis products, has reported a major deal in the Israeli market. Canna-Tech has signed a deal worth at least NIS 192.5 million, in which Together Pharma will cultivate at least five tons of medical cannabis produce annually for Canna-Tech at its Ashkelon farm, over five years for NIS 5.50 per gram, for a total of NIS 27.5 million per year and NIS 137.50 million over the entire period.

In addition, Together pharma will provide Canna-Tech with packing services in the factory that it is setting up for NIS 10 million annually over five years and a total amount of NIS 50 million over the period. Canna-Tech will also transfer a payment of NIS 5 million within three days of signing the agreement.

Together Pharma Chairman Yohanan Danino said, "We are talking about a major, breakthrough deal in the local market, which promotes our business plan and reflects only a small part of the potential revenue and growth of Together Pharma in Israel and around the world."

Together CEO Nissim Bracha added, "The agreement with Canna-Tech represents the realization of our strategy to create large-scale revenue. Canna-Tech is led by excellent businesspeople with major business experience in Israel and abroad and we are ready to immediately fulfil the agreement at the Ashkelon farm in order to supply quality cannabis, according to the new regulation, of the highest standard."

Canna-Tech Owner Shmuel Capuano said, "We are happy about the connection with Together in order to bring a new line to the Israeli and world cannabis market. We are working according to a detailed and precise multi-year plan and we found we had a joint language, personal relations and immediate connection with Together's owners, so that we can realize our vision and bring about change and a real remedy to patients."

Canna-Tech Operations Manager Daniel Mchloof and CEO Netsah Israel said, "We believe that this is the time for action rather than talk and God willing we will quickly bring to patients medical cannabis products of the highest quality."

The deal was initiated, led and supported by Adv. Chagit Weinstock, an expert on international regulation of cannabis and Partner in the Weinstock Zehavi law firm, and supported by Adv. Nir Zohar of the Pearl Cohen Zedek Latzer Baratz law firm.

TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- PRESS RELEASE -- Aleafia Health Inc.’s wholly owned subsidiary, Emblem Cannabis Corp., has secured two Health Canada license amendments that expand processing capacity, allowing for the sale of new product formats at its Paris processing facility. The amendments apply to the licensed and operational Paris location, which processes all of the company’s extraction, packaging and order fulfillment for Canadian and international sales.

As a result of the licence amendments, the company is now authorized to produce and sell new product formats and has adequate, licensed production space to do so.

“These license amendments are well timed, increasing the versatility of our Paris Facility, while ensuring we can move immediately to the production of new cannabis 2.0 formats,” said Aleafia Health CEO Geoffrey Benic. “The additional processing capacity will also allow us to accelerate the production of oil-based products derived from our recent outdoor harvest.”

The first license amendment vastly increases the company’s ability to produce finished cannabis products by authorizing activities including extraction, packaging and labeling in four rooms that were previously only authorized for cannabis cultivation. The amendment doubles the Paris facility’s licensed processing space. The second license amendment permits the company to produce and sell edibles, topicals and extracts to the Canadian market.

Paris Facility Phase II Expansion

Following the issuance of the amended license and closing of corresponding application, the company submitted its final Site Evidence Package (SEP) to Health Canada for the Phase II expansion of its Paris processing facility. The final stage in the company’s license amendment application for the proposed expansion, the SEP demonstrates that the facility is operational ready and meets all Health Canada requirements.

The Paris Phase II expansion, a 30,000-square-foot facility, is entirely dedicated to the extraction, production, packaging and distribution of high-margin, value-added cannabis health and wellness products. The expansion is purpose-built to meet European Union Good Manufacturing Practices (EU-GMP) certification requirements. EU-GMP certified facilities demonstrate the highest level of pharmaceutical-grade quality, and securing the certification (along with applicable import and export permits) will allow Aleafia Health to begin exporting medical cannabis products to the European Union market.